

# Corrigendum to: Longitudinal, Nationwide, Cohort Study to Assess Incidence, Outcomes, and Costs Associated With Complicated Urinary Tract Infection

Joseph J. Carreno,<sup>1</sup> Iris M. Tam,<sup>2</sup> Juliana L. Meyers,<sup>3</sup> Elizabeth Esterberg,<sup>3</sup> Sean D. Candrilli,<sup>3</sup> and Thomas P. Lodise Jr<sup>1</sup>

<sup>1</sup>Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA, <sup>2</sup>Achaogen, Inc., South San Francisco, California, USA, and <sup>3</sup>RTI Health Solutions, Research Triangle Park, North Carolina, USA

“Longitudinal, Nationwide, Cohort Study to Assess Incidence, Outcomes, and Costs Associated With Complicated Urinary Tract Infection” by Joseph J Carreno et al (*Open Forum Infect Dis.* 2019. doi:10.1093/ofid/ofz446)

This study was supported by Cipla. It was incorrect to list Achaogen, Inc., as the sponsor. The product Zemdri (Plazomicin) was acquired by Cipla. Cipla is considered the sponsor. The authors regret this oversight.

---

## Open Forum Infectious Diseases®

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)  
DOI: 10.1093/ofid/ofz536